Micofenolato De Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Accord, is an antimetabolite immunosuppressant presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing lymphocyte proliferation.

GNH USA supplies Micofenolato De Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in the management of immune‑mediated conditions where inhibition of lymphocyte proliferation is required.

- Kidney transplant: helps prevent acute and chronic graft rejection. - Heart transplant: reduces the risk of organ rejection post‑surgery. - Liver transplant: supports long‑term graft survival by suppressing immune response. - Lupus nephritis: diminishes renal inflammation and preserves kidney function.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, sometimes leading to dehydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Tremor: fine shaking of the hands or limbs.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells, increasing infection risk. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Opportunistic infections: severe infections such as cytomegalovirus or fungal disease. - Malignancy: increased risk of certain cancers with long‑term use. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.

- Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess liver function: periodic liver enzyme tests for hepatotoxicity. - Avoid in pregnancy: drug is Category D; use effective contraception. - Use caution in renal impairment: dose adjustment may be required. - Counsel on infection risk: advise prompt reporting of fever or signs of infection. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolate exposure, raising toxicity risk. - Tacrolimus: synergistic immunosuppression, heightening infection risk. - Live vaccines: may cause severe infection; avoid administration.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may reduce absorption of mycophenolic acid. - Rifampin: induces metabolism, decreasing drug levels. - Cholestyramine: binds drug in gut, lowering systemic exposure. - NSAIDs: can exacerbate renal toxicity when combined.